SIMPLIFIED RULES TO IDENTIFY BIO-NAÏVE PATIENTS WITH CROHN’S DISEASE WITH HIGHER LIKELIHOOD OF CLINICAL REMISSION WHEN INITIATING VEDOLIZUMAB VERSUS ANTI-TNF THERAPIES: ANALYSIS OF EVOLVE STUDY DATA

Gerassimos J. Mantzaris  ¹     Andres Yarur  ²     Song Wang  ³     Shashi Adsul  ⁴     Pravin Kamble  ⁵     Michelle Luo  ⁶     Annie Guerin  ⁷     Emma Billmyer  ⁷     Ha Nguyen  ⁷     Brian Bressler  ^8    
1 Evangelismos Hospital, Athens, Greece
² Medical College of Wisconsin, Milwaukee, United States
³ Takeda Pharmaceuticals International Co., Cambridge, United States
⁴ Takeda, Zurich, Switzerland
⁵ Takeda Pharmaceuticals Inc., Cambridge, United States
⁶ Takeda, Cambridge, United States
⁷ Analysis Group, Boston, United States
⁸ University of British Columbia, Vancouver, Canada

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)